HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

L’Oreal To Fuel Continued Dermocosmetics Growth With Skinbetter Science Acquisition

Executive Summary

Phoenix, AZ-based Skinbetter Science “has become one of the fastest growing medical-dispensed skincare brands in the United States,” recording nearly $95m in sales for the 12-month period ended 31 August 2022, and shows “great international potential,” according to L’Oreal leadership.

You may also be interested in...



What Slump? Despite Lockdowns, L'Oreal's China Q2 Sales Grow 6% On Supply Agility, Brand Power

Driven by e-commerce and L’Oréal Luxe, which achieved historic market share, L'Oréal SA's results in China helped fuel 13.4% growth of its overall business in the second quarter to 9.3bn.

L’Oreal Optimistic About Post-Shutdown Growth, Notes Likely Thinning Of Beauty Field

“It's unfortunate, but it's the Darwinian side of this industry,” L’Oreal CEO Jean-Paul Agon said on 16 April while discussing newer players’ prospects for survival through the COVID-19 crisis and L’Oreal’s own first-quarter results – down 4.8% like-for-like, but ahead of the market.

US Interim Funding Bill Gets Biden’s Signature; Window Narrows For Cosmetics, Dietary Supplement Legislation

Passed by the US House and signed into law on 30 September, the Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023, avoids a partial government shutdown and furloughs in FDA user-fee programs. Policy riders stripped from the legislation, including for cosmetics and dietary supplement regulatory changes, could still find their way into a final FY 2023 spending omnibus.

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS152942

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel